TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder breast cancer patients (THRIVE)
远程医疗抵抗运动干预以保持老年乳腺癌患者的剂量强度和活力(THRIVE)
基本信息
- 批准号:10608200
- 负责人:
- 金额:$ 119.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-12-19 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AdherenceAdjuvant ChemotherapyAdministratorAgeAttenuatedBody Weight decreasedBreast Cancer PatientBreast Cancer TreatmentCancer PatientCaringCertificationControl GroupsDataDiagnosisDietDietitianDisease OutcomeDoseDose LimitingEffectiveness of InterventionsElderlyElementsEtiologyEvaluationExerciseFatigueGeneral PopulationGeriatric AssessmentHealth educationHuman ResourcesHybridsIncidenceInferiorIntakeInterventionMental DepressionModelingNutrientOlder PopulationOncologyOutcomeParticipantPatient Outcomes AssessmentsPatientsPersonsPhysical FunctionPlayPopulationProteinsQuality of lifeRandomizedRandomized, Controlled TrialsRecurrenceRecurrent diseaseRiskRoleSEER ProgramSelf-Help DevicesSeveritiesSiteSleepSupplementationSymptomsTabletsTherapeuticToxic effectTreatment ProtocolsTreatment outcomeTreatment-related toxicityWomanagedbehavior changebreast cancer diagnosiscancer therapychemotherapyclinical practicecostdisorder riskefficacy evaluationexercise interventionexperiencefallsfunctional statushuman old age (65+)implementation barriersimplementation interventionimprovedimproved outcomeintervention costmalignant breast neoplasmmembermortalitymuscle formolder womenpredictive modelingpreservationprogramsprotein intakepsychologicpsychosocialresistance exercisetelehealthtranslational goaltreatment centertreatment planningyoung woman
项目摘要
Project Summary/Abstract
More than 276,480 women were diagnosed with breast cancer in 2020, with 120,000 cases occurring in
women 65 years or older. Given the increasing median age of the US population, the number of breast cancers
diagnosed in older women is expected to rise by 50% in the coming decades. Older women with breast cancer
experience worse breast cancer-specific outcomes as compared to younger women, under-treatment is likely
to play a central role. Studies have demonstrated that breast cancer patients who receive <85% of received
dose intensity (RDI), a metric that combines the total dose administered with adherence to the planned
treatment schedule, have a 57% increase in the risk of disease recurrence at 10 years as compared to women
who receive at least 85% RDI. Only 50-76% of breast cancer patients >65 receive an RDI >85, largely due to
increased toxicity of therapy in these patients. Reducing treatment-related toxicity to enhance RDI is
critical to improving disease outcomes among the growing population of older breast cancer patients.
To this end, models predicting for severe chemotoxicity demonstrate that a number of potentially modifiable
factors (commonly assessed as part of the geriatric assessment), are important determinants of chemotoxicity,
including function, depression, and falls (or use of assistive devices). Exercise has a significant positive impact
on each of these modifiable factors, in the general population and in cancer patients. However, data on the
ability of exercise interventions to improve treatment tolerance and preserve dose intensity among older breast
cancer patients are lacking. We propose a randomized controlled trial to assess the effects of a
multicomponent, hybrid telehealth (TH) exercise and protein intake support (the THRIVE Intervention)
on RDI, incidence and severity of chemotoxicities, functional status, muscle mass, and patient
reported outcomes in 270 breast cancer patients age ≥ 65 receiving neo/adjuvant chemotherapy.
Participants will be randomized to the THRIVE Intervention or to a Health Education and Support control
group. The intervention will be delivered through a hybrid model, leveraging the existing Breast Cancer Weight
Loss (BWEL) Trial call center. After 2 in-person, onsite exercise sessions, we will transition to TH sessions
delivered on study provided tablets, by certified exercise coaches who will tailor behavior change to support
adherence relative to symptom burden. To optimize intervention effectiveness, participants will undergo a TH
evaluation of diet adequacy with a registered dietitian, focused on optimal daily protein intake. Protein
supplementation will be provided if needed to achieve 1.2 gm/kg daily intake. The TH focus consolidates
expertise at a well-established call center (BWEL), elevating the potential for broad implementation across the
U.S., including cancer treatment centers with too few patients to justify necessary personnel. The project also
seeks to evaluate intervention cost, as well as the facilitators and barriers to implementation of this TH
intervention, toward the goal of translation to clinical practice upon successful completion of the THRIVE trial.
项目总结/摘要
2020年,超过276,480名女性被诊断患有乳腺癌,其中120,000例发生在
65岁或以上的女性。考虑到美国人口年龄中位数的增加,乳腺癌的数量
预计在未来几十年内,老年妇女的诊断率将上升50%。乳腺癌的早期症状
与年轻女性相比,经历更差的乳腺癌特异性结局,
发挥核心作用。研究表明,接受<85%的乳腺癌患者,
剂量强度(RDI),一种将给予的总剂量与对计划剂量的依从性相结合的指标。
治疗方案,有57%的增加,在疾病复发的风险,在10年相比,妇女
至少有85%的RDI。只有50-76%的>65的乳腺癌患者接受RDI >85,主要是由于
这些患者的治疗毒性增加。降低治疗相关毒性以提高RDI是
对于改善日益增长的老年乳腺癌患者的疾病结局至关重要。
为此,预测严重化学毒性的模型表明,许多潜在的可改变的
因素(通常作为老年评估的一部分进行评估),是化学毒性的重要决定因素,
包括功能、抑郁和福尔斯(或使用辅助设备)。锻炼有显著的积极影响
在普通人群和癌症患者中,这些可变因素中的每一个。然而,数据显示,
运动干预改善老年乳腺癌患者治疗耐受性和保持剂量强度的能力
癌症患者缺乏。我们建议进行一项随机对照试验,以评估
多组分混合远程保健(TH)运动和蛋白质摄入支持(THRIVE干预)
RDI、化疗毒性的发生率和严重程度、功能状态、肌肉质量和患者
报告了270例年龄≥ 65岁接受新/辅助化疗的乳腺癌患者的结局。
参与者将被随机分配到THRIVE干预组或健康教育和支持对照组
组干预将通过混合模式提供,利用现有的乳腺癌体重
丢失(BWEL)试用呼叫中心。在2个现场练习课程之后,我们将过渡到TH课程
通过研究提供的平板电脑,由经过认证的运动教练提供,他们将根据需要改变行为,
坚持相对于症状负担。为了优化干预效果,参与者将接受TH
由注册营养师评估饮食充足性,重点是最佳每日蛋白质摄入量。蛋白
如果需要,将提供补充剂,以达到1.2 gm/kg的每日摄入量。TH重点巩固
在一个成熟的呼叫中心(BWEL)的专业知识,提高了在整个
美国,包括癌症治疗中心,病人太少,不需要必要的人员。该项目还
旨在评估干预成本,以及促进和实施这一TH的障碍
干预,以实现在成功完成THRIVE试验后转化为临床实践的目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nathan A. Berger其他文献
Association of semaglutide with risk of suicidal ideation in a real-world cohort
司美格鲁肽与真实世界队列中自杀意念风险的关联
- DOI:
10.1038/s41591-023-02672-2 - 发表时间:
2024-01-05 - 期刊:
- 影响因子:50.000
- 作者:
William Wang;Nora D. Volkow;Nathan A. Berger;Pamela B. Davis;David C. Kaelber;Rong Xu - 通讯作者:
Rong Xu
Mutant cells defective in poly(ADP-ribose) synthesis due to stable alterations in enzyme activity or substrate availability.
由于酶活性或底物可用性的稳定改变,突变细胞在聚(ADP-核糖)合成方面存在缺陷。
- DOI:
- 发表时间:
1989 - 期刊:
- 影响因子:3.7
- 作者:
S. Chatterjee;N. Hirschler;S. Petzold;S. J. Berger;Nathan A. Berger - 通讯作者:
Nathan A. Berger
Mechanism of epipodophyllotoxin-induced cell death in poly(adenosine diphosphate-ribose) synthesis-deficient V79 Chinese hamster cell lines.
表鬼臼毒素诱导聚(二磷酸腺苷-核糖)合成缺陷的 V79 中国仓鼠细胞系细胞死亡的机制。
- DOI:
- 发表时间:
1990 - 期刊:
- 影响因子:11.2
- 作者:
S. Chatterjee;Divyang Trivedi;S. Petzold;Nathan A. Berger - 通讯作者:
Nathan A. Berger
284 – Transgenic Mouse Model Based on Vsig10L, the First Susceptibility Gene for Familial Barrett's Esophagus
- DOI:
10.1016/s0016-5085(19)36928-8 - 发表时间:
2019-05-01 - 期刊:
- 影响因子:
- 作者:
Durgadevi Ravillah;Anne Baskin;Nathan A. Berger;Ronald A. Conlon;Joseph Willis;Sanford D. Markowitz;Amitabh Chak;Kishore Guda - 通讯作者:
Kishore Guda
Nathan A. Berger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nathan A. Berger', 18)}}的其他基金
TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder breast cancer patients (THRIVE)
远程医疗抵抗运动干预以保持老年乳腺癌患者的剂量强度和活力(THRIVE)
- 批准号:
10450916 - 财政年份:2022
- 资助金额:
$ 119.26万 - 项目类别:
TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder breast cancer patients (THRIVE)
远程医疗抵抗运动干预以保持老年乳腺癌患者的剂量强度和活力(THRIVE)
- 批准号:
10754983 - 财政年份:2022
- 资助金额:
$ 119.26万 - 项目类别:
Case Comprehensive Cancer Center (Case CCC) Cancer Health Disparities SPORE Planning Grant
凯斯综合癌症中心 (Case CCC) 癌症健康差异 SPORE 规划补助金
- 批准号:
10469702 - 财政年份:2018
- 资助金额:
$ 119.26万 - 项目类别:
Case Comprehensive Cancer Center (Case CCC) Cancer Health Disparities SPORE Planning Grant
凯斯综合癌症中心 (Case CCC) 癌症健康差异 SPORE 规划补助金
- 批准号:
10005904 - 财政年份:2018
- 资助金额:
$ 119.26万 - 项目类别:
Case CCC Youth Engaged in Science, 09/01/2022-08/31/2027
案例 CCC青年从事科学,09/01/2022-08/31/2027
- 批准号:
10686983 - 财政年份:2017
- 资助金额:
$ 119.26万 - 项目类别:
Case CCC Youth Engaged in Science, 09/01/2022-08/31/2027
案例 CCC青年从事科学,09/01/2022-08/31/2027
- 批准号:
10514949 - 财政年份:2017
- 资助金额:
$ 119.26万 - 项目类别:
相似海外基金
3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
- 批准号:
10556192 - 财政年份:2023
- 资助金额:
$ 119.26万 - 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
- 批准号:
10315227 - 财政年份:2021
- 资助金额:
$ 119.26万 - 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
- 批准号:
443988 - 财政年份:2021
- 资助金额:
$ 119.26万 - 项目类别:
Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
- 批准号:
20K09011 - 财政年份:2020
- 资助金额:
$ 119.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
- 批准号:
19K09130 - 财政年份:2019
- 资助金额:
$ 119.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
- 批准号:
19K18225 - 财政年份:2019
- 资助金额:
$ 119.26万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
- 批准号:
18K16337 - 财政年份:2018
- 资助金额:
$ 119.26万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
- 批准号:
10005254 - 财政年份:2018
- 资助金额:
$ 119.26万 - 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
- 批准号:
9763320 - 财政年份:2018
- 资助金额:
$ 119.26万 - 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
- 批准号:
18K07341 - 财政年份:2018
- 资助金额:
$ 119.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)